KES-504による前立腺癌の治療成績

概要

論文の詳細を見る
Fifteen cases of advanced prostatic cancer (mostly stages C and D) were treated with Estracyt (KES-504, Estramustine phosphate, 560 mg daily in two divided doses) and clinical findings as well as laboratory and endocrine effects were recorded. The study subjects consisted of two groups, i.e., group I with untreated patients and group II with hormone resistant patients who had been subjected to previous antiandrogenic therapy. Subjective and objective effects were observed to be more favorable in group I patients compared to group II subjects, as far as could be judged from results obtained in the observation period of 3 to 6 months. Decreases in serum levels of LH, FSH and testosterone were observed shortly after the commencement of drug administration. It was concluded that Estracyt exerted clinical effects in these patients to degrees comparable to those in conventional antiandrogenic therapy by estrogen.
泌尿器科紀要刊行会の論文